Loading...
Proteomics Placements And New Platform Pipeline Will Reshape Long-Term Potential
AN
AnalystHighTarget
Not Invested
Community Contributor
Published
08 Jan 26
Views
39
08 Jan
US$0.88
AnalystHighTarget's Fair Value
US$4.05
78.4% undervalued intrinsic discount1Y
-40.6%7D
-5.8%1Y
-40.6%7D
-5.8%You can edit this narrative until Jan 9 6:10 AM. Then, changes will post as Updates.
Author's Valuation
US$4.0578.4% undervalued intrinsic discount
AnalystHighTarget Fair Value